Lilly testing new antibody for South Africa coronavirus variant, says company executive | Article [AMP] | Reuters
▻https://www.reuters.com/article/us-health-coronavirus-lilly-idUSKBN29V1E2
Non publié et sans que soit précisé à quoi correspond le “late-stage”
The company on Tuesday also presented early data from a late-stage trial showing that its combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in COVID-19 patients by 70%.
Data from over 1,000 participants in a late-stage study testing the combination showed 11 COVID-19-related hospitalizations and deaths in patients treated with the therapy, compared with 36 in those on placebo, representing a 70% risk reduction, the company said.